Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Clorox Co (CLX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Clorox Co — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $284.59 (market cap $39.89B), while Clorox Co trades at $94.53 (market cap $11.68B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 3.4× Clorox Co's market cap, and Clorox Co pays a 5.14% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | CLX | |
|---|---|---|
Market Cap | $39.89B | $11.68B |
Sector | Health | Consumer Staples |
52-Week High | $491.22 | $131.43 |
52-Week Low | $278.09 | $86.12 |
Enterprise Value | $38.15B | $14.98B |
Dividend Yield | — | 5.14% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Clorox (CLX) trades at $96.56, up 3.75% today, but remains down over 7% YTD amid declining sales and profitability concerns. The stock shows a bearish technical trend with key support at $91, while fundamentals reveal strong profitability with an 11.18% net margin and a 5.5% dividend yield. Recent corporate actions include a simplified operating structure and CEO transition, with Q2 2026 earnings pending.
The outlook is mixed: a high dividend and recent earnings beats offer value, but bearish analyst sentiment and sales declines pose risks. Upside exists if restructuring drives growth, yet investor caution is warranted given valuation premiums and competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Clorox Co
With a history dating back more than 100 years, Clorox now plays in a variety of categories across the consumer products space, including cleaning supplies, laundry care, trash bags, cat litter, charcoal, food dressings, water-filtration products, and natural personal-care products. Beyond its namesake brand, the firm's portfolio includes Liquid-Plumr, Pine-Sol, S.O.S, Tilex, Kingsford, Fresh Step, Glad, Hidden Valley, KC Masterpiece, Brita, and Burt's Bees. Just shy of 85% of Clorox's sales stem from its home turf.
Read more on CLX →
